Clinical trials: SARS
Vaccine Refusal, Covid19
Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California
The United States (U.S.) is the country with the largest number of infections and deaths due to COVID- 19 and racial/ethnic minorities are disproportionately affected.
- Trial name
- 2VIDA! (NCT05022472)
- Testing
- COVID-19 Individual Awareness and Education., COVID-19 Community Outreach & Health Promotion., COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.
- Where
- 6 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- Britt Skaathun
COVID-19 Testing, Decision Making
Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits
To test competing sets of information for consumers on how to interpret hypothetical SARS-CoV-2 home test kit results and whether they report plans to take CDC-recommended actions to protect themselves and others given their test…
- Trial name
- NCT04758299
- Testing
- decision science-based design
- Where
- United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Barry Dewitt
Covid19, Vaccine Preventable Disease
Study of Gam-COVID-Vac in Adolescents
Double-blind, placebo-controlled study with open dose selection period for safety assessment, tolerance and immunogenicity of the drug "GamKOVID-Vac M, a combined vector vaccine for prevention of coronavirus infection caused by…
- Trial name
- OLSTAD (NCT04954092)
- Testing
- Gam-COVID-vac M
- Where
- 2 sites in Russia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older
This is an international multicenter clinical trial, which is planned to be conducted in several research centers in China and Pakistan.
- Trial name
- NCT05683600
- Testing
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- Where
- 2 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
SARS-CoV-2 Infection
COVID-19 Paediatric VLA2001-321 Study
This is a Randomized, Double-blinded, Active-controlled Study to evaluate the Safety, Tolerability and Immunogenicity of VLA2001 in participants of ≥2 to 12 years.
- Trial name
- NCT05298644
- Testing
- VLA2001, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19, Respiratory Tract Infections
Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration
Project is designed as a comprehensive population-based epidemiological study in Upper-Silesian Conurbation (Poland) aiming at: 1. analysis of available data on incidence and mortality due to COVID-19 and 2.
- Conditions
- Covid19, Respiratory Tract Infections, Severe Acute Respiratory Syndrome, Corona Virus Infection
- Trial name
- EpiSARS2 (NCT04627623)
- Testing
- IgM and IgG antibodies assay
- Where
- Poland
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Silesia
SARS-CoV-2 Rapid Antigen Test
Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19
Physicians, nurses and hospital attendants currently working at the University Clinic of Respiratory and Allergic Diseases Golnik were invited to participate in the pilot study.
- Trial name
- NCT04716088
- Testing
- Rapid antigen test for SARS CoV2
- Where
- Slovenia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
- Trial name
- ENSEMBLE (NCT04505722)
- Testing
- Ad26.COV2.S
- Where
- 225 sites in United States, Argentina and 6 more
- Volunteers
- 44,325 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
Covid19
Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region
Several publications document the occurrence of prolonged or late-onset symptoms beyond 3 weeks after the first clinical manifestations of SARS-COV2 infection.
- Trial name
- COCO_Vi_LATE (NCT04817293)
- Testing
- Questionnaire, medical consultation
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tourcoing Hospital
COVID-19
Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)
The 2019 Coronavirus disease outbreak (COVID-19) was first reported at the end of 2019 in Wuhan China as a severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection.
- Trial name
- NCT05172193
- Testing
- SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
- Where
- 7 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
COVID-19
A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults
This clinical trial aimed to gather safety and immunogenicity data in COVID-19 vaccine-experienced healthy adults. The main questions it aims to answer are: The neutralizing antibodies levels of bivalent mRNA vaccines…
- Trial name
- NCT05907044
- Testing
- RQ3013, RQ3025, RQ3027
- Where
- China
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Yunnan University
Children With Medical Complexity (CMC), COVID-19
ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff
The Coronavirus Disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is a worldwide pandemic that has resulted in large-scale quarantines in cities, states, and countries throughout the world.
- Trial name
- NCT04899245
- Testing
- BinaxNOW Rapid Antigen System
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
COVID-19
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants…
- Trial name
- NCT04904471
- Testing
- Recombinant COVID-19 vaccine (Sf9 cells)
- Where
- 24 sites in Indonesia, Kenya and 3 more
- Volunteers
- 39,663 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
SARS-CoV-2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.
- Trial name
- NCT04523571
- Testing
- BNT162b1
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Pandemic
Motivation, Syringe Exchange, and COVID-19
People who inject drugs (PWIDs) are highly vulnerable to SARS-CoV-2 infection and to the disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), however, rates of SARS-CoV-2 testing and vaccination uptake -vital to…
- Trial name
- NCT05534061
- Testing
- Connect2Test
- Where
- United States
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- University of Oregon
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (≥60 years old) Research purpose: Main purpose: To evaluate the safety and tolerability of different doses of recombinant new coronavirus…
- Trial name
- NCT04550351
- Testing
- Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Healthy Participants
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Primary Objectives: Cohort A: To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCR Cohort A and Cohort A1: To evaluate the safety and…
- Trial name
- NCT04452318
- Testing
- REGN10933 + REGN10987
- Where
- 134 sites in United States, Moldova and 1 more
- Volunteers
- 3,303 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a…
- Trial name
- NCT07536308
- Testing
- OCU500
- Where
- 6 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.